SCHEMBL2932352

SCHEMBL2932352

CC(=O)Nc1n[nH]c2nc(-c3ccc(F)cc3)c(-c3ccnc(S(C)(=O)=O)n3)cc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 10/20 0.40
GSK3A P49840 7/20 0.40
CDK2 P24941 3/20 0.40
RAB9A P51151 1/20 0.38
ADORA3 P0DMS8 1/20 0.38
ADORA2A P29274 1/20 0.38
CYP1A2 P05177 1/20 0.36
MAPK14 Q16539 7/20 0.36
MAPK13 O15264 2/20 0.36
MAPK12 P53778 2/20 0.36
PLK4 O00444 1/20 0.36
AURKA O14965 1/20 0.36
DAPK3 O43293 1/20 0.36
JAK2 O60674 1/20 0.36
PRKCG P05129 1/20 0.36
CDK1 P06493 1/20 0.36
RPS6KB1 P23443 1/20 0.36
TYK2 P29597 1/20 0.36
CLK2 P49760 1/20 0.36
JAK3 P52333 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2928014 0.84 MAPK14 (0.46) GSK3BGSK3ACDK2MAPK14MAPK13
SCHEMBL2932245 0.82 PIK3CA (0.37) GSK3BGSK3ACDK2RAB9AADORA3
SCHEMBL2929634 0.79 MAPK13 (0.46) GSK3BGSK3ACDK2MAPK14MAPK13
SCHEMBL4409899 0.73 ALDH1A1 (0.40) RAB9AMAPK14MAPK13MAPK12MAPK11
SCHEMBL2932911 0.72 EGFR (0.41) GSK3BGSK3ACDK2MAPK14MAPK13
SCHEMBL4407545 0.71 KDM4E (0.38) RAB9AMAPK14MAPK13MAPK12MAPK11
SCHEMBL1385324 0.70 TOP2A (0.43) GSK3BGSK3ACDK2ADORA3ADORA2A
SCHEMBL2410945 0.69 RAB9A (0.56) RAB9APIK3CA
SCHEMBL2925199 0.69 GSK3B (0.55) GSK3BGSK3ACDK2ADORA2ACYP1A2
SCHEMBL4410198 0.68 PTGS2 (0.43) RAB9AMAPK14MAPK13MAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 US disclosed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP disclosed
US-20090286983-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-11-19 US disclosed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 US disclosed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 US disclosed
CN-100354275-C Pyrazolopyridine derivates URIACH Y COMPAGNIA S A J (ES) 2007-12-12 CN disclosed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 US disclosed
CN-1753894-A Pyrazolopyridine derivates URIACH Y COMPAGNIA S A J (ES) 2006-03-29 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167040-A1 Pyrazolopyridine derivates MAPK1, MAP4K2, MAP4K3 GSK3B 1601/4885GSK3A 1871/4885CDK2 69/4885
US-20090286983-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 GSK3B 1958/4885GSK3A 2105/4885CDK2 114/4885
US-20090005377-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 GSK3B 1958/4885GSK3A 2105/4885CDK2 114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.